A recent clinical trial has highlighted the potential of Nelonemdaz in treating patients who have suffered out-of-hospital cardiac arrest. The study, supported by the Ministry of Health and Welfare of the Republic of Korea and GNT Pharma, involved multiple institutions and adhered to strict ethical guidelines, offering new hope for improving survival and recovery outcomes.